Perception, Opportunity in Volatility - Research & Analysis on Zynga Inc and Gilead Sciences, Inc.
February 06 2012 - 9:00AM
Marketwired
This morning, www.MarketFoundations.com announced new reports
highlighting Zynga Inc (NASDAQ: ZNGA) and Gilead Sciences, Inc.
(NASDAQ: GILD). Free research downloads are available at
www.MarketFoundations.com/index.php?coa=ZNGA&cob=GILD.
Economic fundamentals leading into 2012 have set a generally
positive pace with GDP growth likely to pick up through the coming
year. However, there are several important caveats to note as the
world economy continues to face headwinds and risks weigh to the
downside. Positive outlooks are conditional on fiscal policy in
payroll taxes and unemployment insurance benefits and upon the
easing of the European debt situation. A repeat of volatility
experienced in 2011 is likely in 2012, as perceptions about the
strength of the U.S. economy and the euro zone will vary over time
as events unfold.
Despite the current situation, our team continues to identify
high momentum situations with growth potential -- there remains
strong opportunity within careful discretion.
Market Foundations is releasing new coverage on Zynga Inc for
its current position within the technology industry. Zynga Inc.
(Zynga), formerly Presidio Media LLC, is a social game developer
with 232 million average monthly active users (MAUs) in 166
countries. The Company's games are accessible on Facebook, other
social networks and mobile platforms to players globally, wherever
and whenever they want. It operates its games as live services. The
full research report on Zynga Inc (NASDAQ: ZNGA) is available here:
www.MarketFoundations.com/index.php?coa=ZNGA.
Market Foundations has released research on Gilead Sciences,
Inc. for its changing role within the healthcare industry. Gilead
Sciences, Inc. (Gilead) is a biopharmaceutical company. The Company
focuses on the development and commercialization of human
therapeutics for life threatening diseases. The Company has
operations in North America, Europe and Asia Pacific. The Company's
products include Truvada, Atripla, Viread, Emtriva, Hepsera,
AmBisome, Letairis, Ranexa, Vistide and Cayston. The full research
report on Gilead Sciences, Inc. (NASDAQ: GILD) is available here:
www.MarketFoundations.com/index.php?cob=GILD.
About Market Foundations By providing members with financial
information services, we provide the foundation investors need to
build investing intelligence. The difference between consistently
making good investments or bad investments is nothing more than the
right information at the right time.
Contact: Gemma Cunningham Email: Email Contact
www.MarketFoundations.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024